Stock Analysis
Roivant Sciences Ltd. (ROIV) Stock Analysis
Roivant Sciences Ltd. (ROIV) stock analysis covering valuation, fundamentals, technical indicators, risk, AIQ Momentum, analyst catalysts, dividends, and the current AIQ Score.
Roivant Sciences Ltd. (ROIV) currently has an AIQ Score of 57/100, indicating a neutral setup. Momentum is the strongest factor at 78/100. Value is the weakest current factor at 34/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.
ROIV at a Glance
Crawlable current metrics from the latest market-close stock snapshot.
| Metric | Current |
|---|---|
| Price | $40.82 |
| AIQ Score | 57/100 |
| Overall View | Neutral |
| Technical Analysis Consensus | Strong Buy |
| Market Cap | $24.94B |
| P/E Ratio | -32.84 |
| Forward P/E | — |
| EPS | -$0.26 |
| Revenue TTM | $1.44M |
| Dividend Yield | 0.00% |
| Beta | 1.13 |
| Volume | 5.96M |
| 52-week range | $13.40-$42.50 |
| RSI 14 | 66.99 |
| 50-Day SMA | $35.79 |
| 200-Day SMA | $28.91 |
| Analyst Price Target | $40.00 |
| Next Earnings | Nov 9, 2026 |
ROIV
OverviewROIV Stock Analysis Summary
Roivant Sciences Ltd. (ROIV) currently has an AIQ Score of 57/100, indicating a neutral setup. Momentum is the strongest factor at 78/100. Value is the weakest current factor at 34/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.
In a neutral regime, ROIV has AIQ Score of 57/100 with Momentum base of 78/100 and fading Value at 34/100. Wait for component alignment before adding exposure.
Momentum (78/100) leads while Value (34/100) lags. This cross-factor spread creates entry timing uncertainty.
Healthcare · -0.29% stock move · ROIV classified in Biotechnology.
Current Evidence
AlgovestIQ Evidence Summary
Current consensus, supporting evidence, recent changes, and what would strengthen or weaken the view.
Is ROIV Bullish or Bearish Right Now?
ROIV currently has a neutral overall setup. Momentum is the strongest factor at 78/100, while Value is weakest at 34/100. The current evidence suggests a mixed rather than strongly bullish or bearish setup.
- - Quality is supportive at 60/100.
- - Momentum is constructive at 78/100.
- - Risk Resilience is supportive at 61/100.
- - Price is +14.04% above its 50-day SMA.
- - Technical consensus has more buy votes than sell votes (37 vs 6).
- - Value is the current constraint at 34/100.
- - Analyst target implies -2.01% downside from the latest quote.
Current Consensus
ROIV's Technical Analysis Consensus is currently Strong Buy, with 37 buy, 2 neutral, and 6 sell votes. ROIV's 14-day RSI is 66.99, which places the stock in a constructive momentum range. ROIV's beta is 1.13, indicating market sensitivity broadly in line with the market.
What Changed in ROIV?
Recent score-change history is not available in the current snapshot. These are the latest market-close scores instead.
What Would Change the ROIV Outlook?
The current neutral outlook could improve if AIQ moves above 70, momentum recovers, earnings revisions strengthen, and price confirms a stronger trend above the 50-day and 200-day moving averages. It would weaken if AIQ falls below 40, price loses long-term moving-average support, analyst expectations deteriorate, or risk evidence worsens.
AIQ > 70, RSI above 55, price above SMA-50/SMA-200, and positive catalyst or estimate-revision evidence.
AIQ below 40, RSI below 45, loss of SMA-200, negative revisions, or rising volatility and drawdown risk.
ROIV Decision Framework
Public evidence layers, setup checks, and risk context for Roivant Sciences Ltd..
Roivant Sciences Ltd. (ROIV) Stock Analysis
Roivant Sciences Ltd. has an AIQ Score of 57/100 in a Neutral regime. Momentum is strongest at 78/100. Beta is 1.13, above market sensitivity. Review the supporting stock factors together before drawing a conclusion from any single score.
| Evidence Layer | Public Evidence |
|---|---|
| Regime Context | ROIV is in a Neutral AIQ regime with score 57/100. |
| Signal Conflict | The primary conflict is that momentum leads at 78/100 while value lags at 34/100. |
| Factor Evidence | Momentum 78/100 · Value 34/100 · Quality 60/100 · Risk 61/100 |
| Persistence | Current snapshot evidence is shown; historical persistence remains in AIQ Pro. |
Current Setup Checklist
Momentum is the strongest factor at 78/100.
Momentum is 78/100 and RSI (14) is 67.0.
ROIV is in a Neutral regime at 57/100.
Risk factor is 61/100 with beta 1.13 and annual volatility 46.57%.
Current conflict: momentum leads at 78/100 while value lags at 34/100.
ROIV Research Cluster
Ticker-specific paths for valuation, technical analysis, catalysts, dividends, financials, risk, and news.
ROIV Fundamentals
ROIV valuation, profitability, growth, margins, balance-sheet strength, and free cash flow.
ROIV Technical Analysis
ROIV technical setup based on RSI, MACD, moving averages, AIQ Momentum, volume, trend, volatility, and pivots.
ROIV Stock Catalysts
Track ROIV earnings, analyst ratings, price targets, estimate revisions, stock news, and upcoming events.
ROIV Dividend Analysis
ROIV dividend yield, annual dividend, payout ratio, payment history, and income reliability context.
ROIV Financial Data
ROIV revenue, earnings, income statement, balance sheet, cash flow, valuation ratios, and stock metrics.
ROIV Risk Analysis
ROIV volatility, beta, drawdown, Sharpe ratio, VaR, and downside resilience.
ROIV Stock News
ROIV stock news, market tone, recent headlines, and catalyst context.
ROIV vs Gene Editing / Genomics / Biotech Peers
Current peer cohort: ROIV · RXRX · SRPT · VERA · VRNA. Compare AIQ, factor scores, Sharpe ratio and 1-year volatility in one indexable view.
| Peer | AIQ | Value | Momentum | Risk | Sharpe | 1Y Volatility | Compare |
|---|---|---|---|---|---|---|---|
| ROIV Current stock | 57/100 | 34/100 | 78/100 | 61/100 | 2.48 | 46.57% | Current |
| RXRX Recursion Pharmaceuticals | 36/100 | 34/100 | 34/100 | 58/100 | -0.19 | 71.78% | ROIV vs RXRX |
| SRPT Sarepta Therapeutics | 55/100 | 64/100 | 67/100 | 38/100 | 0.58 | 81.30% | ROIV vs SRPT |
| VERA Vera Therapeutics | 42/100 | — | 50/100 | 57/100 | 0.84 | 59.41% | ROIV vs VERA |
| VRNA Verona Pharma | 43/100 | 34/100 | — | 54/100 | 1.41 | 41.05% | ROIV vs VRNA |
Peer cohort is resolved dynamically from the AlgovestIQ universe taxonomy and Compare relationship graph. Data as of Sep 11, 2026.
About the AIQ Score
Methodology for the current stock evidence.
The AlgovestIQ AIQ Score combines multiple dimensions of stock evidence, including momentum, valuation exposure, quality, risk resilience, sentiment context, and timing signals. It is a descriptive research score, not a guarantee of future performance or a personalized recommendation.
View AIQ methodologyFactor Diagnostics
A compact bridge from the AIQ score to the evidence tabs.
Open the return calculator with stock context while purchase price, shares, dates and fees remain user inputs.
AIQ Component Profile
Compare the five component scores on one consistent 0–100 scale.
Review earnings timing, revisions, news pressure, and prior event reactions in one place.
Open catalysts8 recent quarterly periods are available for review.
Checked Sep 11, 2026
Explore factor drivers, conflicts, persistence, and scenario sensitivity in the advanced workspace.
Fundamentals Verdict
Current snapshot fields are separate from reported-quarter statement tables.
Latest period Jun 30, 2026.
Market Confirmation
Technicals are summarized first, with the indicator library behind it.
Risk Alignment
Higher resilience is stronger; exposure metrics stay separate.
Continue Researching ROIV
Open the detailed evidence pages and workflows behind the stock overview read.
Premium Feature
Full AIQ Analysis
AIQ Intelligence
AIQ Pro for ROIV
Scenario Analysis
AIQ Scenario Builder
Portfolio Implication
Related Links
ROIV Stock FAQ
What is ROIV stock price today?
Roivant Sciences Ltd.'s current stock price is $40.82. Use the live quote with AIQ Score, news, and risk context rather than treating price alone as a decision signal.
Is ROIV bullish or bearish right now?
ROIV's bullish or bearish read depends on the current AIQ Score, factor alignment, technical analysis consensus, valuation, risk, and catalyst evidence. A mixed setup should be treated differently from a broad confirmation across those signals.
What is ROIV's market cap?
ROIV's market cap is $24.94B based on the latest completed market-close snapshot from Sep 11, 2026. Use it with P/E ratio, revenue, and growth metrics to frame company size, valuation, and peer comparisons.
What is ROIV's current P/E ratio?
ROIV's current P/E ratio is -32.84 based on the latest completed market-close snapshot from Sep 11, 2026. Read it with revenue growth, margins, EPS, cash flow, and peer valuation rather than using P/E alone.
What is ROIV's RSI?
ROIV's 14-day RSI is 66.99 based on the latest completed market-close snapshot from Sep 11, 2026. RSI should be interpreted with MACD, moving averages, volume, volatility, and price trend.
Is ROIV above its 50-day and 200-day moving averages?
ROIV is 14.04% from its 50-day SMA and 41.20% from its 200-day SMA based on the latest completed market-close snapshot from Sep 11, 2026. Moving-average position should be read with momentum and broader AIQ evidence.
When is ROIV's next earnings date?
ROIV's next earnings date is currently listed as Nov 9, 2026. Earnings can reset revenue, EPS, price target, analyst rating, and catalyst expectations.
Does ROIV pay a dividend?
ROIV's dividend yield is 0.00% based on the latest completed market-close snapshot from Sep 11, 2026. Dividend yield should be read with payout ratio, free cash flow, growth, and balance-sheet strength.